Apotheek Wolfs SRL
Apotheek Wolfs reported total assets of 916,811 € at the end of the 2025 financial year (annual accounts filed with the NBB on 06 Mar 2026).
The score of Apotheek Wolfs shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +38 % Total assets +28 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Apotheek Wolfs's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 112,192 € | ||||
| Equity | 615,329 € | ||||
| Cash | 443,089 € | ||||
| EBITDA | 202,090 € | ||||
| Total assets | 916,811 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 06 Mar 2026
- Year ended 31 Dec 2024filed on 27 Feb 2025
- Year ended 31 Dec 2023filed on 14 Feb 2024
- Year ended 31 Dec 2022filed on 01 Mar 2023
- Year ended 31 Dec 2021filed on 05 Jul 2022
Apotheek Wolfs's financial analysis
- Solvency67.1%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Apotheek Wolfs
Apotheek Wolfs's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0889.535.332
- VAT number
- BE0889535332
- Peppol
- Registered · 0208:0889535332 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 21 May 2007
- Registered office
- 2100 Antwerp
- Latest accounts
- 2025 · filed on 06 Mar 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Apotheek Wolfs (SRL) has been based in Antwerp since 2007, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 112,192 € and equity of 615,329 €; its revenue is not published. Its solvency stands at 67.1%, above the median of its sector (44.2%).
Companies similar to Apotheek Wolfs
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie de Vesnau Manufacture of pharmaceutical preparations Ittre · balance sheet €1.25m
- Geassocieerde Apotheek Piot Retail sale of pharmaceutical products Antwerp · balance sheet 784,378 €
- R&B Farma Retail sale of pharmaceutical products Antwerp · balance sheet 521,346 €
- JM Pharma Care Retail sale of pharmaceutical products Andenne · balance sheet 878,696 €
- Medifar Retail sale of pharmaceutical products Meerhout · balance sheet 921,854 €
- Extrapharm Waremme Retail sale of pharmaceutical products Waremme · balance sheet 936,866 €
- Pharmakaiser Grivegnee Retail sale of pharmaceutical products Liège · balance sheet €1.21m
- De Zorgapotheek Retail sale of pharmaceutical products Hulshout · balance sheet €1.19m
Frequently asked questions about Apotheek Wolfs
What is the revenue of Apotheek Wolfs?
Apotheek Wolfs files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Apotheek Wolfs?
In Belgium, the VAT number is the company number prefixed with BE: BE0889535332 for Apotheek Wolfs, if the company is VAT-registered. Its company number (CBE) is 0889.535.332.
Where is the registered office of Apotheek Wolfs?
According to the CBE register, the registered office of Apotheek Wolfs is in 2100 Antwerp.
What is the equity of Apotheek Wolfs?
At the close of the 2025 financial year, the equity of Apotheek Wolfs amounts to 615,329 €, a solvency of 67.1% of total assets.
Who manages Apotheek Wolfs?
The register lists 1 active mandates at Apotheek Wolfs. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Apotheek Wolfs
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →